Retrophin Inc. (NASDAQ:RTRX)’s share price traded down 4.6% during mid-day trading on Thursday . The company traded as low as $17.45 and last traded at $17.56, with a volume of 370,066 shares traded. The stock had previously closed at $18.40.

A number of equities analysts recently issued reports on the company. BMO Capital Markets restated an “outperform” rating and issued a $25.00 target price on shares of Retrophin in a report on Friday, July 15th. JMP Securities reiterated a “buy” rating on shares of Retrophin in a report on Saturday, July 9th. Zacks Investment Research upgraded Retrophin from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a report on Thursday, July 7th. Finally, Leerink Swann reiterated a “buy” rating and set a $27.00 price target on shares of Retrophin in a report on Monday, June 27th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $23.60.

The firm’s 50-day moving average price is $17.90 and its 200 day moving average price is $15.94. The firm has a market cap of $657.60 million and a price-to-earnings ratio of 9.33.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.36. The firm had revenue of $29 million for the quarter, compared to analyst estimates of $31 million. During the same period in the prior year, the company posted ($0.18) EPS. The firm’s quarterly revenue was up 66.7% compared to the same quarter last year. Analysts expect that Retrophin Inc. will post $0.08 EPS for the current fiscal year.

In other Retrophin news, EVP Alvin Shih sold 8,750 shares of the company’s stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $17.75, for a total transaction of $155,312.50. Following the transaction, the executive vice president now owns 167,084 shares of the company’s stock, valued at approximately $2,965,741. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

A hedge fund recently raised its stake in Retrophin stock. Cornerstone Capital Management Holdings LLC. increased its position in shares of Retrophin Inc. (NASDAQ:RTRX) by 1,449.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 91,421 shares of the biopharmaceutical company’s stock after buying an additional 85,521 shares during the period. Cornerstone Capital Management Holdings LLC. owned approximately 0.25% of Retrophin worth $1,763,000 at the end of the most recent quarter.

Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.